Amgen Inc (AMGN)
268.94
+6.20
(+2.36%)
USD |
NASDAQ |
Apr 19, 16:00
269.10
+0.16
(+0.06%)
After-Hours: 17:04
Amgen Research and Development Expense (Annual): 4.784B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.784B |
| December 31, 2022 | 4.434B |
| December 31, 2021 | 4.819B |
| December 31, 2020 | 4.207B |
| December 31, 2019 | 4.116B |
| December 31, 2018 | 3.737B |
| December 31, 2017 | 3.562B |
| December 31, 2016 | 3.84B |
| December 31, 2015 | 4.07B |
| December 31, 2014 | 4.297B |
| December 31, 2013 | 4.083B |
| December 31, 2012 | 3.38B |
| December 31, 2011 | 3.167B |
| December 31, 2010 | 2.894B |
| December 31, 2009 | 2.864B |
| Date | Value |
|---|---|
| December 31, 2008 | 3.03B |
| December 31, 2007 | 3.266B |
| December 31, 2006 | 3.366B |
| December 31, 2005 | 2.314B |
| December 31, 2004 | 2.028B |
| December 31, 2003 | 1.655B |
| December 31, 2002 | 1.117B |
| December 31, 2001 | 865.00M |
| December 31, 2000 | 845.00M |
| December 31, 1999 | 822.80M |
| December 31, 1998 | 663.30M |
| December 31, 1997 | 630.80M |
| December 31, 1996 | 528.30M |
| December 31, 1995 | 451.70M |
| December 31, 1994 | 323.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
4.116B
Minimum
2019
4.819B
Maximum
2021
4.472B
Average
4.434B
Median
2022
Research and Development Expense (Annual) Benchmarks
| Gilead Sciences Inc | 5.718B |
| Johnson & Johnson | 15.08B |
| Eli Lilly and Co | 9.313B |
| Merck & Co Inc | 30.53B |
| Vertex Pharmaceuticals Inc | 3.163B |